In this article, we are going to take a look at where Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stands against the other one-dollar stocks. The upward trend in the stock market has resumed ...

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.36 per share a year ago.

Michael Mano, the SVP of $KPTI, sold 2,793 shares of the company on 03-04-2025 for an estimated $17,567. We received data on the trade from a recent SEC filing. This ...

$KPTI insiders have traded $KPTI stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Piper Sandler analyst Edward Tenthoff maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday ...

Piper Sandler lowered the firm’s price target on Karyopharm (KPTI) to split-adjusted $15 from $75 and keeps an Overweight rating on the shares following transfer in analyst coverage. The firm ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEWTON, Mass., April 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the ...

Find the latest Karyopharm Therapeutics Inc. KPTI analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Stay updated on market trends for KPTI. Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround Karyopharm Therapeutics (NASDAQ: KPTI) has been beaten down lately ...

Investors in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) need to pay close attention to the stock based on moves in the options ...